key: cord-0791112-kh54yctx
authors: Armengaud, Jean; Delaunay‐Moisan, Agnès; Thuret, Jean‐Yves; van Anken, Eelco; Acosta‐Alvear, Diego; Aragón, Tomás; Arias, Carolina; Blondel, Marc; Braakman, Ineke; Collet, Jean‐François; Courcol, René; Danchin, Antoine; Deleuze, Jean‐François; Lavigne, Jean‐Philippe; Lucas, Sophie; Michiels, Thomas; Moore, Edward R.B.; Nixon‐Abell, Jonathon; Rossello‐Mora, Ramon; Shi, Zhengli; Siccardi, Antonio G.; Sitia, Roberto; Tillett, Daniel; Timmis, Kenneth N.; Toledano, Michel B.; van der Sluijs, Peter; Vicenzi, Elisa
title: The Importance Of Naturally Attenuated Sars‐Cov‐2 In The Fight Against Covid‐19
date: 2020-04-28
journal: Environ Microbiol
DOI: 10.1111/1462-2920.15039
sha: 2c52c59a75eb824c001560b40159e71b1e160854
doc_id: 791112
cord_uid: kh54yctx

The current SARS‐CoV‐2 pandemic is wreaking havoc throughout the world and has rapidly become a global health emergency. A central question concerning COVID‐19 is why some individuals become sick and others not. Many have pointed already at variation in risk factors between individuals. However, the variable outcome of SARS‐CoV‐2 infections may, at least in part, be due also to differences between the viral subspecies with which individuals are infected. A more pertinent question is how we are to overcome the current pandemic. A vaccine against SARS‐CoV‐2 would offer significant relief, although vaccine developers have warned that design, testing, and production of vaccines may take a year if not longer. Vaccines are based on a handful of different designs (1), but the earliest vaccines were based on live, attenuated virus. As has been the case for other viruses during earlier pandemics, SARS‐CoV‐2 will mutate and may naturally attenuate over time (2). What makes the current pandemic unique is that, thanks to state‐of‐the‐art nucleic acid sequencing technologies, we can follow in detail how SARS‐CoV‐2 evolves while it spreads. We argue that knowledge of naturally emerging attenuated SARS‐CoV‐2 variants across the globe should be of key interest in our fight against the pandemic. This article is protected by copyright. All rights reserved.

at least in part, be due also to differences between the viral subspecies with which individuals are infected. A more pertinent question is how we are to overcome the current pandemic. A vaccine against SARS-CoV-2 would offer significant relief, although vaccine developers have warned that design, testing, and production of vaccines may take a year if not longer.

Vaccines are based on a handful of different designs (1), but the earliest vaccines were based on live, attenuated virus. As has been the case for other viruses during earlier pandemics, SARS-CoV-2 will mutate and may naturally attenuate over time (2) . What makes the current pandemic unique is that, thanks to state-of-the-art nucleic acid sequencing technologies, we can follow in detail how SARS-CoV-2 evolves while it spreads. We argue that knowledge of naturally emerging attenuated SARS-CoV-2 variants across the globe should be of key interest in our fight against the pandemic. This article is protected by copyright. All rights reserved.

As expected for any RNA virus (2, 3) , over time, individuals are infected with SARS-CoV-2 variants that typically display some degree of genetic drift, compared with the first isolates of the virus obtained in Wuhan (4) . Indeed, this genetic drift permits SARS-CoV-2 variants to be tracked as they spread around the globe (5). We know from studying viral evolution that genetic drift, in particular derived from genomic deletions, will almost inevitably attenuate the pathogenicity of viruses given enough time (2) . It is entirely plausible that, at present, some individuals, by chance, have already become infected with attenuated versions of SARS-CoV-2. Since self-seclusion of the symptomatic and those at high-risk has been prompted by many authorities, there may have been, concomitantly, selective advantages for potential attenuated variants of SARS-CoV-2 to spread over non-attenuated variants. Fortunately, COVID-19-related hospitalizations and fatalities have decreased several weeks after lock-down measures were installed in various countries. Clearly, the reduction in transmission of the non-attenuated virus has been key in these successes. It cannot be excluded, however, that competition of attenuated strains with the non-attenuated SARS-CoV-2 has also played a role in curbing demand on the health care systems.

Reasoning along these lines, competition of attenuated variants with the non-attenuated SARS-CoV-2 may explain certain particularities in the course of the epidemic at different locations around the globe. Although currently available data on mortality for the SARS-CoV-2-caused pandemic (6) should be interpreted with caution, it seems that case fatality rates tail off even in locations with less effective containment measures. Furthermore, effects of founder events may shed light on the atypical dynamics of some local epidemics, which pair high numbers of infections with low mortality rates. For example, if many of the first local spreaders of the virus were infected with attenuated strains, the spread of the non-attenuated virus may have been blunted from the onset, due to competition. Mathematical modeling may provide support for these hypotheses in further detail, in particular after more reliable data becomes accessible. This article is protected by copyright. All rights reserved.

Currently available sequences for SARS-CoV-2 isolates from across the globe confirm that genetic drift is occurring (3, 4) , although association between these genetic alterations and severity of clinical outcome are sparse. The only hint at attenuation comes from an observation in Singapore, where some SARS-CoV-2 isolates turned out to have a 382-nucleotide deletion in ORF8 of the viral genome (7). This finding is of particular interest, because a deletion of 29 nucleotides appeared in With present-day sequencing prowess, it is feasible to sequence hundreds of thousands of viral genomes, starting from the raw material collected for diagnostic Q-PCR testing. For this, worldwide sequencing platforms could dedicate time and workhorse instruments for sequencing virus-positive samples. We argue that given testing capacity is expanding, it should extend also to samples from asymptomatic individuals. Sample identification of positively-tested individuals would allow determination by follow-up of who was and remained asymptomatic. All viral sequences at centralized sequence repositories then should be annotated for symptomatic or asymptomatic clinical outcomes and other relevant medical parameters, such as age, gender, and co-morbidities (in accordance with appropriate patient privacy legislation). The next step would be to score for specific genetic determinants of the virus, in particular deletions, that are enriched within the pool of isolates derived from confirmed asymptomatic populations but absent in isolates from symptomatic COVID-19 patients.

The focus should be on those genetic determinants of SARS-CoV-2 isolates that would correlate with asymptomatic outcomes and that would be spread at relatively high frequencies. It is key that these potentially attenuated sequences are also found in individuals who otherwise would be at high-risk of developing severe symptoms from COVID-19, such as 60+ year-old individuals with comorbidities that are considered to be risk factors. These individuals could then be approached to be tested for having undergone seroconversion and, if so, for consistent and prolonged asymptomatic status. Statistics should support whether these individuals would be, at least for some time, protected from reinfection with non-attenuated SARS-CoV-2, with a confidence assessment at least comparable with the current standard for phase III clinical trials concerning a typical designer vaccine. In other words, the pandemic, itself, already may have inadvertently performed a 'natural' clinical trial, which, for regular vaccine development, is by far the most time-consuming step.

On the whole, the current global crisis is of a magnitude such that it is feasible to identify currently existing attenuated SARS-CoV-2 variants and to assess their prevalence. Such an effort would be instrumental not only to better understand the evolution of SARS-CoV-2 as it spreads among

Vaccine Types

The evolution and emergence of RNA viruses

We shouldn't worry when a virus mutates during disease outbreaks

Genomic epidemiology of hCoV-19

Phylogenetic network analysis of SARS-CoV-2 genomes

Novel Coronavirus (COVID-19) Infection Map

Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission

Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins

down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

A double epidemic model for the SARS propagation

Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels